12 results · 19ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

QUANTA LITE RUBEOLA (MEASLES) IGG

FDA 510(k)
FDA Class 1 ·Microbiology

Sklar

FDA UDI
SKLAR CORPORATION·10649111118661·MILLER-COLBURN RASP PL/SERR SIZE 1

Grappler Interference Screw System

FDA UDI
Paragon 28, Inc.·00889795141521·1.6 X 20cm, Eyelet K-wire w/ Markings

Grappler Interference Screw System

FDA UDI
Paragon 28, Inc.·00889795153180·Ø1.60mm x 20cm Eyelet Kirschner Wire, 316 LVM

Vu a-POD Prime NanoMetalene

FDA UDI
Seaspine Orthopedics Corporation·10889981139483·Prime NM Implant, 39x27mm x 16mm, 20 Deg

PiCCO Catheter

FDA 510(k)
FDA Class 2 ·Cardiovascular

ALKALINE PHOSPHATASE ISOENZY. SUB. SET

FDA 510(k)
FDA Class 2 ·Clinical Chemistry

ENDOPATH DILATING TIP TROCAR

FDA Adverse Event
Malfunction ·EES-JUAREZ·Product code GCJ·February 20, 1997

SAGITTAL SAW ATTACHMENT

FDA Adverse Event
Malfunction ·SYNTHES GMBH·Product code HWC·February 21, 2013

AP STANDARD RAPID-PORT EZ

FDA Adverse Event
Injury ·ALLERGAN·Product code LTI·January 25, 2011

ACCU-CHEK ® SPIRIT

FDA Adverse Event
Malfunction ·ROCHE DIAGNOSTICS·Product code LZG·July 31, 2014

Anthem Model Numbers: PM3210, PM3212; Allure/Relieve Model Numbers: PM3222, PM3242, PM3262, PM3542, PM3224, PM3244 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration

FDA Enforcement
Class II ·Terminated·St Jude Medical Inc.·October 25, 2017